triazolam has been researched along with nevirapine in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (80.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Daily, JP; Duan, SX; Giancarlo, GM; Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL | 1 |
Ariyoshi, N; Igarashi, T; Ishii, I; Kitada, M; Nakamura, H; Nakasa, H; Ohmori, S | 1 |
1 review(s) available for triazolam and nevirapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for triazolam and nevirapine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delavirdine; Humans; Hydrolysis; Inhibitory Concentration 50; Isoenzymes; Microsomes, Liver; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Triazolam | 2001 |
Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes.
Topics: Adult; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Epoxy Compounds; Erythromycin; Humans; Hydroxylation; In Vitro Techniques; Isoxazoles; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Nevirapine; Pharmaceutical Preparations; Phenols; Steroids; Sulfonamides; Triazolam; Zonisamide | 2002 |